Stem Cells Archives | Page 25 of 200

What are Perinatal Stem Cells? Your Definitive Guide

October 6, 2025 By Cade Hildreth, Founder & President Leave a Comment

Perinatal stem cells are obtained around the time of birth, either shortly before or after. They can be sourced from umbilical cord blood and tissue, placental blood and tissue, as well as amniotic fluid and tissue.

When stem cells were first identified, only two types of stem cells were described: embryonic stem cells and adult stem cells. Today, a diverse range of stem cells exist, because the diversity of adult stem cell types has substantially expanded and induced pluripotent stem cells (iPSCs) have since been discovered. [Read more…]

Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease

October 6, 2025 By BioInformant Team Leave a Comment

A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]

Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF

October 2, 2025 By BioInformant Team Leave a Comment

SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.

Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]

HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies

October 2, 2025 By BioInformant Team Leave a Comment

HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders

Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases. [Read more…]

The Pros and Cons of Stem Cell Research in 2026

October 2, 2025 By Cade Hildreth, Founder & President Leave a Comment

Interested to understand the importance of stem cell research and recent advancements within this field of study? Today, there are approximately 250 companies worldwide that are developing stem cell products for therapeutic use in humans to address a diverse range of chronic and acute conditions. There are also around astounding 500,000+ scientific publications about stem cells that have been published today in peer-reviewed journals.

In this article, we’ll explore the pros and cons of stem cell research. Let’s dive in.

In this article:

Pros of Stem Cell Research
Cons of Stem Cell Research

[Read more…]